Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110. This decision follows Merck’s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Merck continues to advance clinical programs and to scale-up manufacturing for two investigational medicines, MK-7110 and MK-4482 (molnupiravir); molnupiravir is being developed in collaboration with Ridgeback Bio. “We are grateful to our collaborators who worked with us on these vaccine candidates and to the volunteers in the trials,” said Dr.

Source: Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates – Merck.com

3 COMMENTS

  1. I love your blog.. very nice colors & theme.
    Did you make this website yourself or did you hire someone to do
    it for you?
    Plz answer back as I’m looking to design my own blog
    and would like to find out where u got this from.
    thank
    you

LEAVE A REPLY

Please enter your comment!
Please enter your name here